---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-058902"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2022-09-26T23:59:59+00:00"
generated_at: "2026-06-23T07:32:54.504261+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics appoints Jerry McLaughlin to Board of Directors, effective Oct 1, 2022

## Summary
- Jerry McLaughlin appointed as Class II director, expanding board from six to seven members.
- McLaughlin qualifies as independent director under NASDAQ rules; serves on Audit and Compensation Committees.
- Compensation: $50k annual cash retainer, $7.5k Audit Committee fee, and options for 23k shares vesting over 36 months.
- McLaughlin is CEO of Life Biosciences, former CEO of Neos Therapeutics and AgeneBio; 30 years biopharma experience.
- Press release and updated company overview presentation furnished as Exhibits 99.1 and 99.2.

## SEC filing metadata
- accession: 0001213900-22-058902
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2022-09-26T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390022058902/0001213900-22-058902-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390022058902/ea166296-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-058902
- JSON: https://secwatch.observer/filing/0001213900-22-058902.json
- Plain text: https://secwatch.observer/filing/0001213900-22-058902.txt

## Key facts
- Executive change
  Jerry McLaughlin was appointed as director at Allarity Therapeutics, Inc..
  - Action: appointed
  - Role: director
  source text: To fill the vacancy, the Board appointed the following individual as a director of the Company, effective as of October 1, 2022: Class II Director : Jerry McLaughlin,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390022058902/0001213900-22-058902-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.